Yahoo Finance59m
Does This News From the FDA Make Eli Lilly a Buy for 2025?
Lilly sells tirzepatide, a compound sold for weight loss under the name Zepbound and for type 2 diabetes under the name ...
MedPage Today3d
FDA Says Compounded Tirzepatide Must Exit the Market
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
BioSpace5h
7 Indications for GLP-1s Beyond Weight Loss
Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...
Daily18h
Tirzepatide taken for weight loss may lead to Colonic Ischemia: Case report
A recent case published in the journal ACG CASE REPORTS JOURNAL found a possible risk of colonic ischemia caused by the usage ...
Investing5h
Novo Nordisk shares rebound despite disappointing CagriSema trial results
Jefferies analysts weighed in, noting that CagriSema’s 20.4% weight loss at 68 weeks closely mirrored the 20.9% seen in Lilly ...
Too Old to Operate2d
Lower Risk of Cardiovascular Death with Tirzepatide in Heart Failure
The following is a summary of “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity,” published in the ...
Tennessee woman accused of selling fake weight loss drugs as counterfeit concerns grow
The woman was accused of selling counterfeit versions of popular weight loss drugs, including Ozempic and Wegovy. Experts say ...
Investing3d
Hims & Hers shares tumble as FDA resolves obesity drug shortage
The FDA's latest decision could reshape the market dynamics for obesity drugs, as compounded versions were allowed under U.S. regulations during the shortage. Hims & Hers Health's stock movement today ...